Sarepta Therapeutics (SRPT) News Today $118.97 -0.50 (-0.42%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC WainwrightDecember 22 at 3:43 AM | americanbankingnews.comSell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys ProjectionsDecember 20 at 8:06 PM | markets.businessinsider.comSarepta wins $115.2 million US drug patent verdict from Japan's Nippon ShinyakuDecember 20 at 4:45 PM | reuters.comHere are highlights from Thursday’s Analyst Blog:December 20 at 10:04 AM | finance.yahoo.comSarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC WainwrightHC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday.December 19 at 8:20 AM | marketbeat.comSarepta completes enrollment in the EMERGENE study of SRP-9003December 18, 2024 | markets.businessinsider.comSarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4December 18, 2024 | businesswire.comNational Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)National Bank of Canada FI trimmed its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 94.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 387 shares of the biotechnology company'December 18, 2024 | marketbeat.comHans Lennart Rudolf Wigzell Sells 10,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) StockDecember 17, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in StockSarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.December 16, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,696,354 shares of the biotechnology company'sDecember 16, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Stifel Financial CorpStifel Financial Corp grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,207 shares of the biotechnDecember 16, 2024 | marketbeat.comWorld Investment Advisors LLC Purchases Shares of 19,358 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)World Investment Advisors LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,358 shares of the biotechnology cDecember 15, 2024 | marketbeat.comSarepta Therapeutics, Inc. (SRPT): A Bull Case TheoryDecember 14, 2024 | insidermonkey.comFDA's new accelerated approval guidance to benefit rare disease drug development, analysts believeDecember 13, 2024 | proactiveinvestors.comGarden State Investment Advisory Services LLC Takes $2.12 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Garden State Investment Advisory Services LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,936 shares of the biotechnology company'sDecember 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Y Intercept Hong Kong Ltd trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 79.0% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 7,947 shares of the biotechnology company's stock after selling 29,809 shares during the pDecember 13, 2024 | marketbeat.comOptimistic Future Growth and Strategic Partnerships Drive Buy Rating for Sarepta TherapeuticsDecember 12, 2024 | markets.businessinsider.comHighTower Advisors LLC Decreases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)HighTower Advisors LLC cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,333 shares of the biotechnology company's stock after selling 10December 11, 2024 | marketbeat.comTwo Sigma Advisers LP Lowers Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Two Sigma Advisers LP cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 78.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 128,034 shares of the biotechnology company's stock aDecember 9, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. reduced its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 24.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,855 shares of the biotechnology cDecember 9, 2024 | marketbeat.comMain Management ETF Advisors LLC Purchases Shares of 5,432 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Main Management ETF Advisors LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 5,432 shares of the biotechnology company's stock, valueDecember 8, 2024 | marketbeat.comWellington Management Group LLP Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 32.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,726,613 shares of the biotechnology company'sDecember 8, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Kathryn Jean Boor Sells 1,636 SharesDecember 7, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-three brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold reDecember 7, 2024 | marketbeat.comKathryn Jean Boor Sells 1,636 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) StockSarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company's stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.December 6, 2024 | marketbeat.comWhy Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?December 6, 2024 | msn.comSoros Fund Management LLC Invests $25.80 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Soros Fund Management LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 206,583 shares of the bioteDecember 6, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,278 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.0% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 268,203 shares of the biotechnology company's sDecember 5, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)The Manufacturers Life Insurance Company trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,778 sharesDecember 4, 2024 | marketbeat.comEdgestream Partners L.P. Purchases Shares of 18,459 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Edgestream Partners L.P. acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,459 shares of the biotechnology company's stock,December 3, 2024 | marketbeat.comSarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial RisksDecember 3, 2024 | markets.businessinsider.comSarepta price target lowered to $75 from $80 at H.C. WainwrightDecember 2, 2024 | markets.businessinsider.comSarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth PotentialDecember 2, 2024 | markets.businessinsider.comZacks Research Issues Positive Estimate for SRPT EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities research analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued on Wednesday, November 27th. Zacks Research analyst S. Ganoria now anticipates that theDecember 2, 2024 | marketbeat.comErste Asset Management GmbH Purchases Shares of 636,065 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Erste Asset Management GmbH acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 636,065 shares of the biotechnology company's stock, valueDecember 1, 2024 | marketbeat.comBellevue Group AG Acquires 92,027 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Bellevue Group AG increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 36.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,348 shares of the biotechnologyDecember 1, 2024 | marketbeat.comPoint72 Europe London LLP Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Point72 Europe London LLP purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,983 shares of the biotechnology company's stock, valued at apprDecember 1, 2024 | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 30, 2024 | gurufocus.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Braidwell LPBraidwell LP decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 370,400 shares of the biotechnology company's stock aNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Buys 44,425 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Eventide Asset Management LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 272,954 shares of the biotechNovember 29, 2024 | marketbeat.comTaconic Capital Advisors LP Invests $624,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Taconic Capital Advisors LP purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,000 shares of the biotechNovember 29, 2024 | marketbeat.comSummit Partners Public Asset Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Summit Partners Public Asset Management LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 547.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 138,118 shares of the biotechNovember 29, 2024 | marketbeat.comAlkeon Capital Management LLC Raises Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Alkeon Capital Management LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 633,845 shares of the biotechnoNovember 29, 2024 | marketbeat.comSarepta Therapeutics Receives Buy Rating from Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth PotentialNovember 28, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Has $76.40 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Charles Schwab Investment Management Inc. grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 611,749 shares of the biotechnology coNovember 28, 2024 | marketbeat.comArrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz StrongNovember 28, 2024 | msn.comSarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price TargetNovember 28, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)November 28, 2024 | markets.businessinsider.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.650.60▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼1511▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Moderna News Today Viatris News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Catalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
